Your browser doesn't support javascript.
loading
Smart Medication ™, an Electronic Diary for Surveillance of Haemophilia Home Care and Optimization of Resource Distribution.
Mondorf, Wolfgang; Eichler, Hermann; Fischer, Ronald; Holstein, Katharina; Klamroth, Robert; Nimtz-Talaska, Antje; Wermes, Cornelia; Richter, Heinrich; Severin, Kai.
Afiliación
  • Mondorf W; Praxis und Labor Haemostaseologie, Haemostas-Frankfurt, Frankfurt am Main, Germany.
  • Eichler H; Transfusionsmedizin und Hämostaseologie, Universitätsklinikum des Saarlandes, Homburg, Germany.
  • Fischer R; Hämophiliezentrum, Universitätsklinikum Gießen/Marburg, Gießen, Germany.
  • Holstein K; Hämophiliezentrum, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany.
  • Klamroth R; Vivantes Klinikum, Zentrum für Hämophilie und Hämostaseologie, Berlin, Germany.
  • Nimtz-Talaska A; Praxis für Kinder- und Jugendmedizin, Frankfurt (Oder), Germany.
  • Wermes C; Hämophilie-Zentrum Hildesheim und Hannover, Hildesheim, Germany.
  • Richter H; Hämophilie-Zentrum, Münster Westfahlen, Germany.
  • Severin K; Praxis für Hämatologie und Onkologie, Köln, Germany.
Hamostaseologie ; 39(4): 339-346, 2019 Nov.
Article en En | MEDLINE | ID: mdl-30620988
This report describes the technical features and potential advantages of the application of electronic haemophilia treatment diary smart medication ™ and an evaluation of real-life electronic treatment data collected from haemophilia patients. Since 2012, a total of 663 patients from 30 German haemophilia treatment centres (HTCs) have used the device. Data of nine HTCs were merged for real-life data analysis. Patients were divided into four subgroups according to above versus below mean values for annual factor consumption (AFC) and annual joint bleeds (AJB), respectively. The largest subgroup comprised patients with low mean AFC and AJB less than 2.25 (group A: 42%). Second largest was the group with low mean AJB but high AFC (group B: 32%), suggesting that resources could be saved in some patients. The group with low AFC but high AJB may need increased factor dosing (group D: 13%). Patients who showed a high mean AJB despite high AFC (group C: 13%) may require special medical attention, such as pharmacokinetic-adapted treatment modification or orthopaedic measures. Smart medication ™ enables the HTC to quickly identify patients in need of treatment changes and, thus, to plan individualized therapy modifications prior to patient visits. The growing pool of real-life data facilitates data analysis and may play an important role in the optimization of resource distribution.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Telemedicina / Hemofilia A / Servicios de Atención de Salud a Domicilio Tipo de estudio: Prognostic_studies / Screening_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Hamostaseologie Año: 2019 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Telemedicina / Hemofilia A / Servicios de Atención de Salud a Domicilio Tipo de estudio: Prognostic_studies / Screening_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Hamostaseologie Año: 2019 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania